⚠️ Inadequate preparation is one of the leading contributors to ibogaine-related adverse events and fatalities. Cardiac screening, complete medication disclosure, and proper substance tapers are non-negotiable safety steps — not optional recommendations.

Why Preparation Matters

Ibogaine is a powerful alkaloid with a narrow therapeutic window and a well-documented cardiac risk profile. A 2012 case-series review by Koenig & Hilber published in Molecules identified QT interval prolongation and fatal ventricular arrhythmias as the primary mechanisms behind ibogaine-related deaths — nearly all of which occurred in people with undetected cardiac risk factors or concurrent drug use. Thorough preparation does not eliminate risk, but it substantially reduces it.

Step 1: Medical Screening (Mandatory)

Reputable clinics require a full medical workup before accepting any patient. If a provider skips these steps, that is a serious red flag. The following are standard components of evidence-based pre-treatment screening, as outlined by MAPS clinical protocols and peer-reviewed safety literature:

Cardiac Evaluation

  • 12-lead ECG (electrocardiogram): Screens for prolonged QTc interval. Most protocols require a QTc below 450 ms in males and 470 ms in females. A QTc above 500 ms is an absolute contraindication in virtually all published protocols (Litjens & Brunt, 2016).
  • Echocardiogram: Recommended to rule out structural heart disease, cardiomyopathy, or valvular abnormalities.
  • Cardiac history review: Disclose any personal or family history of arrhythmias, sudden cardiac death, heart failure, or Brugada syndrome.

Laboratory Blood Panel

  • Comprehensive metabolic panel (CMP): Assesses liver and kidney function. Ibogaine is heavily metabolized by CYP2D6 in the liver; liver disease can cause dangerous drug accumulation.
  • Complete blood count (CBC): Rules out underlying blood disorders.
  • Electrolyte panel: Hypokalemia and hypomagnesemia independently prolong the QT interval and compound ibogaine's cardiac risk (Alper et al., 2012). Any electrolyte imbalances must be corrected before treatment.
  • Thyroid function (TSH, T3, T4): Thyroid dysfunction affects both cardiac rhythm and drug metabolism.
  • Liver enzymes (AST, ALT, GGT): Elevated liver enzymes may indicate impaired ibogaine clearance.
  • Urine drug screen: Confirms substance use and detects drugs that could cause fatal interactions.

Psychiatric Evaluation

A structured psychiatric assessment should rule out or stabilize the following, which are relative or absolute contraindications depending on severity:

  • Personal or first-degree family history of schizophrenia or schizoaffective disorder
  • Active bipolar I disorder (especially manic phase)
  • Severe, untreated PTSD with psychotic features
  • Active suicidal ideation with intent or plan

Ibogaine produces prolonged, intense visionary states lasting 8–12 hours. Individuals with psychosis-spectrum disorders may experience significant decompensation during or after the experience (Schenberg et al., 2014).

Step 2: Absolute Contraindications — Do Not Proceed

The following conditions represent absolute contraindications in published clinical guidance. Proceeding in the presence of these factors has been associated with documented fatalities:

  • QTc interval >500 ms on ECG
  • Known personal or familial channelopathy (Brugada syndrome, Long QT syndrome types 1–3)
  • Severe liver disease or hepatic failure (Child-Pugh Class C)
  • Recent myocardial infarction (within 6 months)
  • Active congestive heart failure
  • Use of QT-prolonging medications within the required washout period (see Step 3)
  • Opioids in system without supervised medical taper or confirmed withdrawal completion
  • Current use of lithium
  • Pregnancy
  • Uncontrolled epilepsy

A January 2021 review in Frontiers in Pharmacology (Mash et al.) confirmed that the majority of documented ibogaine-associated deaths involved at least one of the above factors being present at the time of treatment.

Step 3: Medication Tapering and Washout Periods

This is one of the most clinically critical and most frequently mishandled aspects of preparation. Never stop medications abruptly without physician supervision. Some withdrawals (benzodiazepines, alcohol, barbiturates) are life-threatening.

Opioids

Combining ibogaine with opioids in the body carries a risk of fatal respiratory depression. The standard protocol, as used in multiple observational studies (Noller et al., 2018; Brown & Alper, 2017), is:

  • Short-acting opioids (heroin, oxycodone, hydrocodone): Wait a minimum of 12–24 hours after last use. The patient should ideally be in mild-to-moderate withdrawal — this is the intended therapeutic window.
  • Methadone: Requires a supervised taper to ≤30 mg/day, ideally ≤10–20 mg/day, before treatment. Methadone has its own QT-prolonging properties and an extremely long half-life. Many protocols require a minimum 2–4 week taper period at low doses.
  • Buprenorphine (Suboxone, Subutex): Requires a supervised taper and transition to short-acting opioids, or a minimum 3–7 day abstinence, due to high mu-receptor affinity that can block ibogaine's mechanism and trigger precipitated withdrawal. Some protocols require up to 72 hours of abstinence minimum (Mash, 2018).

QT-Prolonging Drugs — Mandatory Washout

The following drug classes independently prolong the QT interval and create additive risk with ibogaine. Documented protocols require discontinuation and washout before treatment (Koenig & Hilber, 2012):

  • Antipsychotics (haloperidol, quetiapine, ziprasidone, risperidone): minimum 5 half-lives washout, consult prescribing physician
  • Tricyclic antidepressants (amitriptyline, imipramine): minimum 5 half-lives; abrupt discontinuation risks severe withdrawal — taper required
  • SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine): minimum 2-week washout for most; fluoxetine requires 4–6 weeks due to long half-life of its active metabolite
  • Certain antibiotics (azithromycin, fluoroquinolones): avoid use in the 7 days before treatment
  • Antiarrhythmics (amiodarone, sotalol, quinidine): absolute contraindication; consult cardiologist — amiodarone has a half-life of 40–55 days
  • Stimulants (amphetamines, cocaine, MDMA): minimum 2-week abstinence; increases cardiovascular strain and interaction risk
  • Cannabis: Abstain for at least 24–48 hours; cannabis can affect heart rate and interact unpredictably during the experience

A full QT drug interaction database is maintained at CredibleMeds.org, which classifies drugs by cardiac risk level.

MAOIs and Serotonergic Drugs

Ibogaine has monoamine-modulating properties. Combining it with MAOIs, high-dose SSRIs, tramadol, or triptans raises the theoretical risk of serotonin syndrome. Most protocols require a 2-week MAOI washout minimum (14 days for irreversible MAOIs).

Step 4: Dietary and Lifestyle Preparation

Fasting Protocol

Most clinical protocols require fasting for 4–6 hours before ibogaine administration to reduce nausea and vomiting risk. Ibogaine reliably causes nausea and emesis, and aspiration is a documented risk if the stomach is full. Some protocols extend the fast to 8–12 hours. Confirm the specific requirement with your provider.

Hydration and Electrolytes

In the 48–72 hours before treatment, prioritize hydration and electrolyte balance. As noted above, hypokalemia and hypomagnesemia worsen QT prolongation. If electrolytes are low on labs, your provider should correct them before proceeding — commonly with oral magnesium glycinate or IV supplementation depending on severity.

Alcohol Abstinence

Abstain from alcohol for a minimum of 48–72 hours before treatment. Alcohol acutely disrupts electrolyte balance, impairs liver metabolism, and interacts with ibogaine's cardiovascular effects.

Diet in the Days Before

While ibogaine does not have a formally established MAOI-type dietary restriction, most experienced practitioners recommend:

  • Eating light, easily digestible meals in the 24–48 hours before treatment
  • Avoiding large, high-fat meals that slow gastric emptying
  • No grapefruit or grapefruit juice (CYP3A4 inhibitor — may affect drug metabolism)

Step 5: Psychological and Logistical Preparation

Setting Intentions

Research on psychedelic-assisted therapy consistently identifies set (mindset) and setting as contributors to outcome (Griffiths et al., 2006, foundational in the broader field). Before treatment:

  • Identify clear, specific intentions. What do you hope to address or understand?
  • Engage in preparatory sessions with the treating therapist or facilitator — reputable clinics include at least 1–2 intake calls or in-person preparation sessions
  • Journal about fears, goals, and areas of resistance
  • Avoid major life stressors in the week before treatment where possible

Logistical Requirements

  • Do not drive for at least 24–48 hours post-treatment. Ibogaine causes ataxia (loss of coordination) and visual disturbances that persist well beyond the acute visionary phase. Some individuals experience residual effects for 48–72 hours.
  • Arrange for a trusted person to accompany you to and from the facility
  • Plan for a minimum of 3–7 days at the treatment facility or residence post-administration before traveling internationally if applicable
  • Secure your daily responsibilities: work, childcare, medical appointments
  • Prepare your integration environment: a calm, supportive home setting for the week after treatment

Inform Your Treatment Team Completely

Full disclosure is a safety issue, not a bureaucratic requirement. Tell your provider about:

  • Every prescription, over-the-counter drug, and supplement you take
  • All substances used, including frequency and last use date
  • Any cardiac symptoms: palpitations, fainting, chest pain, shortness of breath
  • Any psychiatric hospitalizations or diagnoses, including those not currently treated
  • Any family history of sudden unexplained death or cardiac events

Concealing information from your treatment team directly increases your risk of a serious adverse event.

Step 6: What Reputable Providers Should Do

You have the right to ask your provider for documentation of their safety protocols. A legitimate ibogaine provider should:

  • Require and review all screening labs and ECG results before confirming your booking
  • Have a licensed medical professional (physician or nurse practitioner) present or immediately available during the session
  • Have continuous cardiac monitoring (pulse oximetry and ECG monitoring) during the acute phase
  • Have crash cart or defibrillation equipment on-site
  • Provide a clear emergency protocol and have established relationships with local emergency services
  • Offer integration support or referrals for the weeks following treatment

Walk away from any provider who dismisses your questions about these protocols, does not require medical screening, or pressures you to proceed despite concerns.

Consequences of Skipping Preparation: Documented Cases

The Global Ibogaine Therapy Alliance (GITA) and peer-reviewed literature have documented that inadequate preparation is a common thread across adverse outcomes:

  • A 2012 review by Alper et al. in Alkaloids: Chemistry and Biology identified 19 fatalities temporally associated with ibogaine use, most involving either undetected cardiac pathology or concurrent drug use — both preventable with proper screening.
  • Multiple case reports document fatal arrhythmias in individuals who had not disclosed methadone use or had QTc values above safe thresholds (Koenig & Hilber, 2012).
  • At least one case report documents serious adverse outcomes following failure to complete buprenorphine washout, resulting in acute withdrawal precipitation mid-session (Mash et al., 2021).

Frequently Asked Questions

Most reputable providers recommend beginning the preparation process 4–8 weeks before your scheduled treatment date. This window allows time for medical labs and ECG results to be reviewed, for any medication tapers to be safely completed under physician supervision (methadone tapers in particular can take 4+ weeks), for electrolyte imbalances to be corrected, and for preparatory psychological sessions to take place. If you are on buprenorphine, fluoxetine, or antiarrhythmic medications, the required washout periods alone may push your timeline to 6 weeks or more. Starting late compresses these timelines dangerously.
No — not without explicit confirmation from both your prescribing physician and your ibogaine treatment team. Many commonly prescribed medications, including antidepressants, antipsychotics, antiarrhythmics, and even some blood pressure medications, are QT-prolonging or interact with ibogaine's metabolism. Never stop any medication abruptly on your own — some discontinuations (benzodiazepines, SSRIs, beta-blockers) require a supervised taper to avoid withdrawal complications that are dangerous in their own right. Bring a complete medication list to your treatment provider at the earliest possible stage, not the day before.
A 12-lead ECG is the minimum standard — but a more conservative and increasingly common protocol also includes an echocardiogram to detect structural heart disease that an ECG alone cannot reliably identify. If you have any cardiac symptoms (palpitations, syncope, exertional chest pain), a personal or family history of sudden cardiac death, or you are over age 40, an echocardiogram and cardiology consultation should be considered essential. The ECG primarily screens for QTc prolongation and conduction abnormalities, but does not fully evaluate valvular disease, cardiomyopathy, or Brugada pattern in all cases (Litjens & Brunt, 2016).
Yes. Most clinical protocols require abstinence from cannabis for at least 24–48 hours before ibogaine administration, and many recommend stopping 1–2 weeks prior. Cannabis affects heart rate and autonomic tone, and combining it with ibogaine's cardiovascular effects is unpredictable. Additionally, high-dose THC use close to treatment may intensify the visionary experience in ways that are difficult to navigate and may complicate clinical monitoring. CBD is generally considered lower risk than THC, but should also be disclosed to your provider as it is a CYP enzyme inhibitor that may affect ibogaine metabolism.
The post-treatment period is as important as preparation. In the first 24–72 hours, most individuals are fatigued, emotionally raw, and may have residual ataxia (coordination difficulties) and visual sensitivity. Do not drive, make major decisions, or return immediately to high-stress environments. Prioritize rest, gentle nutrition, and hydration. Avoid reintroducing substances — the neuroplastic window following ibogaine is both an opportunity and a vulnerability. Engage with integration support: therapy, journaling, or structured reflection with a trained counselor. If you experience chest pain, palpitations, severe confusion, or signs of psychiatric crisis after treatment, seek emergency medical care immediately and inform them of ibogaine use.
Proceeding without cardiac screening is directly linked to fatal outcomes in the published literature. Ibogaine blocks hERG potassium channels in the heart, a mechanism that prolongs the QT interval and creates conditions for torsades de pointes — a potentially fatal ventricular arrhythmia. Individuals with pre-existing QT prolongation, Brugada syndrome, hypokalemia, or undetected structural heart disease may have no symptoms beforehand and would have no way of knowing their risk without screening. Alper et al. (2012) identified undetected cardiac pathology as the single most consistent finding across ibogaine-related fatalities. There is no safe workaround for cardiac screening.

Sources

  • Alper, K.R., Stajić, M., & Gill, J.R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412.
  • Koenig, X., & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules, 20(2), 2208–2228.
  • Litjens, R.P.W., & Brunt, T.M. (2016). How toxic is ibogaine? Clinical Toxicology, 54(4), 297–302.
  • Mash, D.C., et al. (2021). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence. Frontiers in Pharmacology, 12, 583–601.
  • Noller, G.E., Frampton, C.M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46.
  • Brown, T.K., & Alper, K. (2017). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36.
  • Schenberg, E.E., et al. (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of Psychopharmacology, 28(11), 993–1000.
  • Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. Available at: www.ibogainealliance.org
  • CredibleMeds QTDrugs List. Arizona CERT / University of Arizona. Available at: crediblemeds.org

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.